CVD Risk Reduction and Lipid Management - 62

Anacetrapib Effects on LDL-C and HDL-C
100

LDL-C

120 100

HDL-C

80 LDL-C (mg/dL) (SE)

60

-39.8% (P<0.001)

HDL-C (mg/dL) (SE)

80 60 40 20 0

+138.1% (P<0.001)

40 Anacetrapib Placebo
Baseline

20

Anacetrapib Placebo
Baseline

0

6

12

18

24

30

46

62

76

6

12

18

24

30

46

62

76

Study Week
Anacetrapib n = 804 771 716 687 646 Placebo n = 803 759 741 743 735 604 711 568 691 540 666

Study Week
Anacetrapib n = 776 757 718 687 647 Placebo n = 766 761 741 744 736 607 711 572 691 543 666

Cannon CP et al. N Engl J Med. 2010;363:2406-2415.



CVD Risk Reduction and Lipid Management

Table of Contents for the Digital Edition of CVD Risk Reduction and Lipid Management

CVD Risk Reduction and Lipid Management - 3
CVD Risk Reduction and Lipid Management - 5
CVD Risk Reduction and Lipid Management - 6
CVD Risk Reduction and Lipid Management - 7
CVD Risk Reduction and Lipid Management - 8
CVD Risk Reduction and Lipid Management - 9
CVD Risk Reduction and Lipid Management - 10
CVD Risk Reduction and Lipid Management - 11
CVD Risk Reduction and Lipid Management - 12
CVD Risk Reduction and Lipid Management - 13
CVD Risk Reduction and Lipid Management - 14
CVD Risk Reduction and Lipid Management - 15
CVD Risk Reduction and Lipid Management - 16
CVD Risk Reduction and Lipid Management - 17
CVD Risk Reduction and Lipid Management - 18
CVD Risk Reduction and Lipid Management - 19
CVD Risk Reduction and Lipid Management - 20
CVD Risk Reduction and Lipid Management - 21
CVD Risk Reduction and Lipid Management - 22
CVD Risk Reduction and Lipid Management - 23
CVD Risk Reduction and Lipid Management - 24
CVD Risk Reduction and Lipid Management - 25
CVD Risk Reduction and Lipid Management - 26
CVD Risk Reduction and Lipid Management - 27
CVD Risk Reduction and Lipid Management - 28
CVD Risk Reduction and Lipid Management - 29
CVD Risk Reduction and Lipid Management - 30
CVD Risk Reduction and Lipid Management - 31
CVD Risk Reduction and Lipid Management - 32
CVD Risk Reduction and Lipid Management - 33
CVD Risk Reduction and Lipid Management - 34
CVD Risk Reduction and Lipid Management - 35
CVD Risk Reduction and Lipid Management - 36
CVD Risk Reduction and Lipid Management - 37
CVD Risk Reduction and Lipid Management - 38
CVD Risk Reduction and Lipid Management - 39
CVD Risk Reduction and Lipid Management - 40
CVD Risk Reduction and Lipid Management - 41
CVD Risk Reduction and Lipid Management - 42
CVD Risk Reduction and Lipid Management - 43
CVD Risk Reduction and Lipid Management - 44
CVD Risk Reduction and Lipid Management - 45
CVD Risk Reduction and Lipid Management - 46
CVD Risk Reduction and Lipid Management - 47
CVD Risk Reduction and Lipid Management - 48
CVD Risk Reduction and Lipid Management - 49
CVD Risk Reduction and Lipid Management - 50
CVD Risk Reduction and Lipid Management - 51
CVD Risk Reduction and Lipid Management - 52
CVD Risk Reduction and Lipid Management - 53
CVD Risk Reduction and Lipid Management - 54
CVD Risk Reduction and Lipid Management - 55
CVD Risk Reduction and Lipid Management - 56
CVD Risk Reduction and Lipid Management - 57
CVD Risk Reduction and Lipid Management - 58
CVD Risk Reduction and Lipid Management - 59
CVD Risk Reduction and Lipid Management - 60
CVD Risk Reduction and Lipid Management - 61
CVD Risk Reduction and Lipid Management - 62
CVD Risk Reduction and Lipid Management - 63
CVD Risk Reduction and Lipid Management - 64
CVD Risk Reduction and Lipid Management - 65
CVD Risk Reduction and Lipid Management - 66
https://www.nxtbookmedia.com